Lilly's Mounjaro leads to more and faster weight loss than Novo obesity drug, data analysis finds
Overweight or obese adults lost more weight and shed pounds faster using Eli Lilly's Mounjaro than those taking Novo Nordisk's popular rival weight loss drug, according to an analysis of health rec...
Study finds Mounjaro outperforms Ozempic in overweight & obese adults: Truveta's VP of Research
Dr. Nick Stucky, VP of Research at Truveta, joins 'Fast Money' to talk the results of a study comparing weight-loss drugs Mounjaro and Ozempic.
Mounjaro outperforms Ozempic for weight loss in adults, study says
Eli Lilly and Co (NYSE:LLY)'s diabetes drug Mounjaro is more effective for weight loss than Novo Nordisk (NYSE:NVO)'s Ozempic in overweight or obese adults, a real-world analysis by Truveta Researc...
Mounjaro is more effective for weight loss than Ozempic: study reveals
Mounjaro – a popular treatment for diabetes is more effective for losing weight than Ozempic, as per a large study of real-word data by Truveta Research.
Eli Lilly (LLY) Stock Outperforms Industry YTD: Here's Why
Lilly (LLY) is making rapid pipeline progress in areas like obesity, diabetes and Alzheimer's. Mounjaro and Zepbound are expected to be key top-line drivers for Lilly.
Will Eli Lilly Be Worth More Than Tesla by 2027?
Eli Lilly's shares climbed rapidly in recent years. The pharma giant's track record of bringing highly successful drugs into the market means there's a long growth runway.
GLOBALT Investments' Keith Buchanan on his top stock picks: WMT, LLY, JPM
Keith Buchanan, GLOBALT Investments senior portfolio manager, joins 'Squawk Box' to discuss his top stock picks, including Walmart, Eli Lilly, and JPMorgan Chase.
Ignore Eli Lilly. These 2 Stocks Are Better Buys Right Now
Pfizer and AbbVie face headwinds right now, but their long-term outlooks remain bright. Both stocks trade for a bargain today.
Lilly (LLY) to Build $2.5B Plant to Meet Increased Drug Demand
Through this expansion, Eli Lilly (LLY) intends to expand its global manufacturing footprint to support the rising demand for its diabetes and obesity portfolio.
Medicare's exclusion of weight-loss drug coverage under fire
Medicare's decades-old exclusion of weight-loss drug coverage is coming under scrutiny amid mounting evidence that Wegovy and similar medications have health benefits that extend well beyond sheddi...
Eli Lilly Just Got One Step Closer to Dethroning Ozempic. Time to Buy the Stock?
Eli Lilly's approval for its obesity drug Zepbound is a huge step forward in its attempt to take market share from its top rival Novo Nordisk. The combination of Mounjaro and Zepbound could reach n...
Eli Lilly plans $2.5B site in Germany to expand injectable manufacturing capacity
Eli Lilly and Co (NYSE:LLY) has announced plans for a new $2.5 billion high-tech manufacturing site in Germany to expand its global parenteral (injectable) product and device manufacturing network....
Eli Lilly to build $2.5 billion plant in Germany to support rising demand for obesity, diabetes drugs
Shares of Eli Lilly & Co. LLY, +0.04% rose 0.67% in premarket trading Friday after drug giant announced plans to spend $2.5 billion to build a new manufacturing facility in Germany. The new facilit...
Retail investors crowd into Eli Lilly after weight-loss drug approval
Retail flows into Eli Lilly spiked to a more than two-year high in November, as small investors rushed to buy the stock after the U.S. pharma major received a highly anticipated approval for its we...
Weight loss drugs and stocks: Breaking down the GLP1 market for investors
Weight loss drugs are at the forefront of demand in the pharmaceutical sector as major drug manufacturers Novo Nordisk (NVO) and Lilly (LLY) undergoing clinical trials for new GLP-1 drugs. And, one...
Related Companies